       Management Team
Mark Leuchtenberger
Mark Leuchtenberger has been our President, Chief Executive Officer and a member of our board of directors since March 2010, bringing experience in commercial operations, business development and preparing biopharmaceutical companies for product approval and commercialization. Prior to joining us, he served as President and Chief Executive Officer of Targanta Therapeutics Corporation, a biopharmaceutical company, from September 2006 until August 2009, following Targanta’s acquisition. As President and Chief Executive Officer at Targanta, he led its initial public offering in 2007 and its acquisition in 2009. From March 2002 to August 2006, Mr. Leuchtenberger served as the President and Chief Executive Officer of Therion Biologics Corporation, a privately-held cancer vaccine company. Prior to Therion, Mr. Leuchtenberger was a senior officer at Biogen Idec Inc., where he led the Avonex development and launch in the United States and subsequently managed North American and international commercial operations. Mr. Leuchtenberger received his M.B.A. from the Yale School of Management and his B.A. from Wake Forest University. He currently serves on the Executive Committee of the Massachusetts Biotechnology Council Board of Directors and as a trustee for Beth Israel Deaconess Medical Center. He is a co-founder of Albor Biologics, Inc. and Alvos Therapeutics, Inc. We believe that Mr. Leuchtenberger possesses specific attributes that qualify him to serve as a member of our board of directors, including the perspective and experience he brings as our Chief Executive Officer, which brings historic knowledge, operational expertise and continuity to our board of directors, and his prior executive experience as chief executive officer of two previous biotechnology companies.
Robert Conerly
Chief Financial Officer
Robert A. Conerly has been our Chief Financial Officer and Vice President, Finance since June 2002. Prior to joining us, Mr. Conerly served as Chief Financial Officer and Vice President of Finance of Pharmion Corporation from January 2001 to December 2001. Prior to Pharmion, Mr. Conerly spent six years at AstraZeneca PLC, both in the U.S. and Europe, in numerous financial positions. As Director of Business Performance for the then newly-merged AstraZeneca, he led senior management in the development and monitoring of performance objectives. Mr. Conerly began his professional career at Price Waterhouse where he advanced to Senior Manager and worked in Audit Advisory Services, the Entrepreneurial Services Center and the Mergers and Acquisitions Group. Mr. Conerly earned his M.B.A. and B.S. from the University of Missouri.
Erin Duffy, Ph.D.
Chief Scientific Officer
Erin M. Duffy, Ph.D. has been our Chief Scientific Officer since July 2011. She was previously our Vice President, Discovery Research from May 2007 to July 2011, Executive Director, Structure-Based Drug Discovery from January 2007 to May 2007, Senior Director, Structure-Based Drug Discovery from January 2005 to January 2007 and Director, Structure-Based Drug Discovery from January 2002 to January 2005. Prior to joining us in January 2002, Dr. Duffy was the Associate Director of Innovative Discovery Technologies at Achillion Pharmaceuticals, Inc. Prior to that, she was a computational chemist with Pfizer Global Research and Development. Dr. Duffy earned her Ph.D. and M.S. in chemistry from Yale University and her B.S. from Wheeling Jesuit College.
Scott Hopkins, M.D.
Chief Medical Officer
Scott J. Hopkins, M.D. has been our Chief Medical Officer since September 2008 and previously was our Vice President, Clinical Development from October 2002 to September 2008. Until October 2002, Dr. Hopkins served on our scientific advisory board and as our consultant since October 2000. Prior to joining us as an employee, Dr. Hopkins held global responsibility for the clinical development of anti-infective agents at Pfizer Inc., including development of Zithromax, Diflucan and Trovan. Dr. Hopkins earned his M.D. from the University of Virginia School of Medicine and his A.B. from Princeton University.
Matthew A. Wikler, M.D.
Chief Development Officer
Matthew A. Wikler, M.D. is our newly appointed Chief Development Officer, effective April 30, 2012. Prior to joining us, Dr. Wikler served as President and Chief Executive Officer of IASO Pharma Inc. from February 2010 to October 2011, as the corporate officer of IASO Pharma Inc. from October 2011 to April 2012 and as a director of IASO Pharma Inc. from February 2010 to April 2012. Prior to that, Dr. Wikler was the Chief Medical Officer of the Institute for One World Health from February 2009 to February 2010 and the President and Chief Executive Officer and a director of IASO Pharma Inc. from November 2006 to February 2009. Before that, he held senior level positions at Mpex Pharmaceuticals, Peninsula Pharmaceuticals (acquired by Johnson & Johnson), ViroPharma, Bristol-Myers Squibb Company, Ortho-McNeil Pharmaceutical (division of Johnson & Johnson), Bio-Pharm Clinical Services (acquired by Omnicare), Burroughs Wellcome and Smith Kline & French/Smith Kline Beecham. Dr. Wikler also spent two years at the U.S. Food and Drug Administration, serving as Deputy Director, Division of Anti-Infective Drug Products for a portion of that time. He currently serves on the Board of Directors for the Clinical and Laboratory Standards Institute and previously served as the Chairman of the Antimicrobial Susceptibility Testing Subcommittee. Dr. Wikler earned his B.A. from Franklin and Marshall College, his M.D. from Temple University, completed his Infectious Diseases Fellowship at the Hospital of the University of Pennsylvania and is a Fellow of the Infectious Diseases Society of America. He received an M.B.A. from the University of Pennsylvania’s Wharton School of Business.
Jarrod Longcor
Vice President, Corporate Development
Jarrod Longcor has been our Vice President, Corporate Development since June 2011. From July 2009 to June 2011, Mr. Longcor was our Senior Director, Business Development and from October 2007 to July 2009, he was our Director, Business Development. Mr. Longcor has over 15 years of industry experience with 13 years of experience doing business development. Prior to joining us, Mr. Longcor served as Senior Director of Business Development at MaxCyte, Inc. from March 2006 to July 2007, where he was responsible for developing and executing a market partnering strategy and for corporate and product marketing as well as alliance management. From September 2005 to March 2006, Mr. Longcor was a business development consultant for several small biotechnology and pharmaceutical companies and from January 2004 to September 2005, he served as the Senior Director of Business Development for Advancis Pharmaceutical Corporation. Mr. Longcor received his M.B.A. from the Erivan K. Haub School of Business at St. Joseph’s University, Masters of Medicine from Boston University School of Medicine and his B.S. from Dickinson College.
Anthony Sabatelli, Ph.D., J.D.
Vice President, Intellectual Property, Authorized House Counsel
Anthony Sabatelli, Ph.D., J.D. has been our Vice President, Intellectual Property and Authorized House Counsel since January 2008. Currently, Dr. Sabatelli is also an adjunct professor of chemistry at the University of New Haven and from August 2010 through December 2010, Dr. Sabatelli was an adjunct professor of chemistry at Central Connecticut State University. From December 2002 through December 2007, Dr. Sabatelli was our Assistant Vice President. Dr. Sabatelli joined us in December 2002 from Merck & Co., where he was Assistant Patent Counsel from April 2000 to November 2002 and Senior Patent Attorney from May 1997 to April 2000. Prior to joining Merck, he was Patent Counsel at the Procter & Gamble Company. Dr. Sabatelli began his professional career at Procter & Gamble’s Miami Valley Laboratories as a research and development scientist before he moved to their patent department. Dr. Sabatelli earned his Ph.D. from Yale University, his J.D. from Salmon P. Chase College of Law and his B.S. from Fairfield University.
Colleen Wilson
Director, Human Resources
Colleen Wilson has been our Director, Human Resources since January 2011. Prior to joining us, she was Manager, Human Resources at Infinity Pharmaceuticals, Inc. from March 2009 to January 2011, where she was responsible for recruiting new members to the leadership team and for playing an important role in organizational growth and design initiatives. From May 2007 to February 2009, Ms. Wilson was Senior Manager, Human Resources, at Targanta Therapeutics Corporation, where she played a key role in establishing the human resources function for the new company and in developing the commercial sales infrastructure. She also held human resources roles at Genzyme Corporation from September 2006 to May 2007 and Therion Biologics from November 2002 to June 2006. Ms. Wilson received her B.S. from the University of New Hampshire and is currently pursuing an M.B.A. from Babson College.
|
President and Chief Executive Officer